Drug approved by the FDA
for the treatment of Duchenne.
CureDuchenne was an early funder.
CureDuchenne funded research projects
have advanced to human clinical trials
Our lives were changed forever…
“We didn’t know anything about Duchenne and felt isolated that there was no one we could turn to… CureDuchenne has hosted several workshops that have been invaluable in providing knowledge on the care, treatment and future of our son, but, even more importantly, has enabled us to spend time with other Duchenne families…”
Duchenne is a devastating muscle disease.
It’s the most common and severe form of muscular dystrophy. Those affected with Duchenne lose their ability to walk, feed themselves, breathe independently and succumb to heart failure. But there’s hope through new pharmacological and gene-based therapies. You can help make a difference.
NEWPORT BEACH, Calif. – (BUSINESS WIRE) – CureDuchenne, a national venture philanthropy nonprofit focused on finding a cure for Duchenne muscular dystrophy (DMD), announced today a $500,000 investment into 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, in an effort to advance […]
CURE DUCHENNE NEWS
Investment advances pre-clinical development of novel exon skipping therapies for treatment of patients with Duchenne muscular dystrophy October 17, 2018 08:00 AM Eastern Daylight Time LA JOLLA, Calif.–(BUSINESS WIRE)–Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, announced today that CureDuchenne has made an equity investment […]